<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794677</url>
  </required_header>
  <id_info>
    <org_study_id>MM6997</org_study_id>
    <nct_id>NCT00794677</nct_id>
  </id_info>
  <brief_title>Effects of Ezetimibe on the Absorption of Oxidized Cholesterol</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Plasma Appearance of 7-Ketocholesterol After an Oral Bolus in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Schering-Plough</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of Zetia™ (ezetimibe) 10 milligrams (mg) on
      the absorption of oxysterol into the blood following a meal containing oxysterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a number of cholesterol-lowering drugs available that can lower blood cholesterol
      to a healthier level. Zetia™ (ezetimibe) 10 mg is available by prescription for the treatment
      of high cholesterol. While Zetia has been shown to inhibit the absorption of dietary
      cholesterol into the bloodstream, its effects on oxysterol absorption from the diet have not
      been completely evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus</measure>
    <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus</measure>
    <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Blinded study medication (ezetimibe 10 mg or matching placebo in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_label>ezetimibe</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not currently pregnant or lactating and is highly unlikely to conceive

          -  Body Mass Index (BMI) between 20-30 kilograms per meter squared (kg/m2) inclusive.

          -  Body weight, as reported by patient, stable (±2 kg) for &gt;6 weeks

          -  Plasma low density lipoprotein cholesterol (LDL-C) between 130 and 180 milligrams per
             deciliter (mg/dL) inclusive. Note: One retest allowed.

          -  Triglyceride (TG) concentrations ≤150 mg/dL. Note: One retest allowed.

          -  Fasting blood glucose &lt;110 mg/dL and hemoglobin A1c (HbA1C) ≤ 6 percent at Visit 1.
             Note: One retest allowed.

          -  Liver transaminases (ALT, AST) ≤1.5 x upper limit of normal (ULN) and no active liver
             disease. Note: One retest allowed.

          -  Creatine Phosphokinase (CPK) ≤2x ULN. Note: One retest allowed.

          -  Willingness to maintain a stable diet for the duration of the study.

          -  Can understand and comply with study procedures and signs a written informed consent.

          -  Patient is ≥80 precent compliant with dosing during Placebo Run-In Period or, in the
             opinion of the investigator, is able to maintain ≥80 percent therapy compliance during
             the active treatment period of the study.

        Exclusion Criteria:

          -  Lipid-lowering therapy and replacement of this therapy with study medication is
             considered inappropriate by the investigator.

          -  Consumes an average of more than 2 alcoholic drinks per day.

          -  Smokes.

          -  Currently engages in a vigorous exercise regimen or intensive exercise bouts &gt;4x per
             month.

          -  Treated with any other investigational drug within 30 days of Visit 1.

          -  Hypersensitivity or intolerance to ezetimibe or any component of this medication.

          -  Any condition or situation which poses a risk to the patient or interfere with
             participation in the study.

          -  Congestive heart failure.

          -  Uncontrolled cardiac arrhythmias.

          -  History of myocardial infarction, stroke, or any other clinical manifestation of
             coronary, cerebral, or peripheral vascular disease.

          -  Uncontrolled hypertension

          -  Impaired renal function, nephrotic syndrome or other clinically significant renal
             disease at Visit 1.

          -  Active or chronic hepatobiliary or hepatic disease.

          -  History of irritable bowel syndrome, ileal bypass, gastric bypass or any
             gastrointestinal disorder/condition associated with malabsorption.

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins.

          -  Type I or Type II diabetes mellitus.

          -  Disorders of the hematologic, digestive, or central nervous systems including
             cerebrovascular disease and degenerative disease that would limit study evaluation or
             participation.

          -  Human Immunodeficiency Virus (HIV) positive.

          -  History of cancer within the past 5 years (except for successfully treated basal and
             squamous cell carcinomas).

          -  History of uncontrolled psychiatric illness or drug/alcohol abuse within the past 5
             years. Individuals with psychiatric illness adequately controlled and stable on
             pharmacotherapy may be enrolled at the discretion of the investigator.

          -  Lipid-lowering agents taken within 6 weeks and fibrates taken within 8 weeks prior to
             visit 3.

          -  Cardiovascular medications are acceptable provided the patient has been on a stable
             regimen for at least 6 weeks prior to Visit 3 and indicates a willingness to continue
             the stable regimen for the duration of the study.

          -  Supplementation with antioxidants beyond a standard multivitamin for the duration of
             the study.

          -  Psyllium, other fiber-based laxatives, and/or over the counter (OTC) therapies known
             to affect serum lipid levels taken within 6 weeks of Visit 3.

          -  Female patients receiving hormone replacement therapy, any estrogen antagonist/agonist
             or hormonal contraceptives.

          -  Treatment with cyclosporine except for ophthalmic indication

          -  Anti-obesity medications such as orlistat or sibutramine taken within 3 months prior
             to Visit 1.

          -  Therapeutic doses of systemic corticosteroids except inhaled steroid therapy (for
             example, Pulmicort®) maintained on a stable dosing regimen for at least 6 weeks prior
             to randomization (Visit 3) and throughout the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Krauss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cholesterol Research Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <results_first_submitted>January 30, 2009</results_first_submitted>
  <results_first_submitted_qc>July 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2009</results_first_posted>
  <last_update_submitted>July 31, 2009</last_update_submitted>
  <last_update_submitted_qc>July 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ronald Krauss, M.D.</name_title>
    <organization>Children's Hospital Oakland Research Institute</organization>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Oxysterol</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Zetia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place in 2007 through search of a clinical research center database, mailings to homes, and posted flyers in the Berkeley, California area.</recruitment_details>
      <pre_assignment_details>55 participants screened; 29 excluded because they did not meet inclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe</title>
          <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily received as the first or second intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe</title>
          <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily received as the first or second intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.05" spread="7.54"/>
                    <measurement group_id="B2" value="50.09" spread="14.28"/>
                    <measurement group_id="B3" value="50.99" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus</title>
        <description>Log of Area-under-the-plasma-concentration curve (AUC 0-8hrs) of 7-ketocholesterol after an oral bolus in patients with primary hypercholesterolemia after treatment with ezetimibe versus placebo</description>
        <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus</title>
          <description>Log of Area-under-the-plasma-concentration curve (AUC 0-8hrs) of 7-ketocholesterol after an oral bolus in patients with primary hypercholesterolemia after treatment with ezetimibe versus placebo</description>
          <population>per protocol</population>
          <units>Log(mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.925" spread="0.166"/>
                    <measurement group_id="O2" value="2.177" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical significance was determined for a standard two-period crossover design using JMP software (Version 5.0, SAS Institute. Cary, NC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.252</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.112</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus</title>
        <description>Log Cmax of 7 ketocholesterol after an oral bolus in patients with primary hypercholesterolemia.</description>
        <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus</title>
          <description>Log Cmax of 7 ketocholesterol after an oral bolus in patients with primary hypercholesterolemia.</description>
          <population>Per protocol</population>
          <units>Log(mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.973" spread="0.156"/>
                    <measurement group_id="O2" value="1.246" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.273</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.102</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Log(Fasting Plasma Levels of Diet-derived Oxysterols (7-ketocholesterol))</title>
        <time_frame>Fasting measurements after 6 weeks on ezetimibe vs placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Log(Fasting Plasma Levels of Diet-derived Oxysterols (7-ketocholesterol))</title>
          <population>Per protocol</population>
          <units>Log(mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.119" spread="0.124"/>
                    <measurement group_id="O2" value="-1.070" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.089</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Log (AUC of Plasma Total Cholesterol) After an Oral Bolus</title>
        <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
        <population>Per protocol, restricted to changes that were nonnegative because there is no log for a negative number</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Log (AUC of Plasma Total Cholesterol) After an Oral Bolus</title>
          <population>Per protocol, restricted to changes that were nonnegative because there is no log for a negative number</population>
          <units>Log(mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.928" spread="0.213"/>
                    <measurement group_id="O2" value="2.719" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.470</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Log (AUC of Plasma Triglyceride) After an Oral Bolus</title>
        <time_frame>Over 8 hours after 6 weeks of treatment with ezetimibe or placebo</time_frame>
        <population>Per protocol, one subject eliminated because the AUC was negative and cannot be log transformed</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Log (AUC of Plasma Triglyceride) After an Oral Bolus</title>
          <population>Per protocol, one subject eliminated because the AUC was negative and cannot be log transformed</population>
          <units>Log(mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.894" spread="0.139"/>
                    <measurement group_id="O2" value="5.044" spread="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change of Apolipoprotein B</title>
        <time_frame>Fasting measurements after 6 weeks on ezetimibe vs placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Apolipoprotein B</title>
          <population>Per protocol</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.990" spread="1.648"/>
                    <measurement group_id="O2" value="-2.577" spread="2.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15.412</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.569</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Percent change was calculated relative to the value at the end of the 2-week placebo run in period, which was either 3-weeks (for measurements made at the end of the first period) or 9 week earlier (for those made at the end of the second period).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change of Low Density Lipoprotein Cholesterol</title>
        <time_frame>Fasting measurements after 6 weeks on ezetimibe vs placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Low Density Lipoprotein Cholesterol</title>
          <population>Per protocol</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.891" spread="2.497"/>
                    <measurement group_id="O2" value="-1.045" spread="2.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0000001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.866</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Percent change was calculated relative to the value at the end of the 2-week placebo run in period, which was either 3-weeks (for measurements made at the end of the first period) or 9 week earlier (for those made at the end of the second period).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change in High Density Lipoprotein Cholesterol</title>
        <time_frame>Fasting measurements after 6 weeks on ezetimibe vs placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High Density Lipoprotein Cholesterol</title>
          <population>Per protocol</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.936" spread="2.134"/>
                    <measurement group_id="O2" value="-7.333" spread="1.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.397</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.893</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Percent change was calculated relative to the value at the end of the 2-week placebo run in period, which was either 3-weeks (for measurements made at the end of the first period) or 9 week earlier (for those made at the end of the second period).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change of Non-high Density Lipoprotein Cholesterol</title>
        <time_frame>Fasting measurements after 6 weeks on ezetimibe vs placebo</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe (10 mg/day) once daily received as the first or second intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily received as the first or second intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Non-high Density Lipoprotein Cholesterol</title>
          <population>Per protocol</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.675" spread="2.326"/>
                    <measurement group_id="O2" value="-1.322" spread="1.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0000001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.353</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.220</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Percent change was calculated relative to the value at the end of the 2-week placebo run in period, which was either 3-weeks (for measurements made at the end of the first period) or 9 week earlier (for those made at the end of the second period).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald M Krauss</name_or_title>
      <organization>Children's Hospital Oakland Research Institute</organization>
      <phone>510.450.7912</phone>
      <email>rkrauss@chori.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

